← Back to Search

H2 Receptor Antagonist

Intravenous Famotidine for Indigestion

Phase 4

Recruiting

Research Sponsored by Stony Brook University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subject Age ≥ 18 years of age

Patient diagnosed with dyspepsia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 1 hour

Awards & highlights

Study Summary

This trial aims to compare the effectiveness of intravenous famotidine (an H2 receptor antagonist) and Maalox/Mylanta (an oral antacid) in treating dyspepsia in

Who is the study for?

This trial is for adults over 18 with dyspepsia, experiencing upper abdominal pain of at least a moderate level. It's not suitable for those with severe kidney issues, pregnant or nursing women, people who can't take oral meds, have bowel obstruction, recently took proton pump inhibitors, or are allergic to the study medications.Check my eligibility

What is being tested?

The study compares intravenous Famotidine and oral Maalox/ Mylanta in treating indigestion in emergency department patients. The goal is to see which medication reduces pain more effectively within an hour based on patient-reported pain levels.See study design

What are the potential side effects?

Possible side effects include headaches, constipation or diarrhea from Famotidine; and chalky taste, stomach cramps or nausea from Maalox/ Mylanta. Reactions vary by individual.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with indigestion.

Select...

I have severe upper abdominal pain.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 1 hour

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 1 hour

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Verbal Numerical Pain Score

Secondary outcome measures

Need for Rescue Medications

Satisfaction with Assigned Medication

Trial Design

2Treatment groups

Active Control

Group I: Intravenous FamotidineActive Control1 Intervention

Patients in this group will receive 20 mg of intravenous famotidine.

Group II: Oral MaaloxActive Control1 Intervention

Patients in the group will receive 30 ml of oral Maalox/ Mylanta.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stony Brook UniversityLead Sponsor

216 Previous Clinical Trials

39,891 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment phase for this investigation currently ongoing?

"Yes, data provided on clinicaltrials.gov indicates that this research study is actively seeking participants. The trial's initial posting was on November 9th, 2023 and its most recent update occurred on January 26th, 2024. This study aims to enroll 80 patients from a single location."

Answered by AI

What is the total number of participants enrolled in this clinical trial?

"Affirmative. Details available on clinicaltrials.gov indicate that this ongoing medical trial is actively seeking participants. Initially posted on November 9, 2023, and most recently revised on January 26, 2024, the study aims to enroll approximately 80 patients from a single location."

Answered by AI

What are the potential risks associated with intravenous administration of famotidine for individuals?

"Our team at Power has assessed the safety of Intravenous Famotidine as a 3 on our scale, considering this Phase 4 trial indicates that the treatment is already sanctioned for use."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Famotidine and Antacids for Treatment of Dyspepsia

Adam Singer 2023. "Famotidine and Antacids for Treatment of Dyspepsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06241183.

All > Dyspepsia